

16th MEET THE PROFESSOR - DIGITAL EVENT 2020

Advanced International Breast Cancer Course

ASYNCR DISTANCE LEARNING

SEPTEMBER 25th, 2020 - SEPTEMBER 24th, 2021

LIVE WEBINAR

OCTOBER 8TH (3.50 P.M. - 6.50 P.M.)

OCTOBER 9TH (4 P.M. - 6.15 P.M.)

fad.accmec.org



GYMNASIVM
MNIVM DISCIPLINA

PRINCIPE PASCHALI SICONIA
FRANCISCO IOANNE SVPERANTIO EQ. ET FEDERICO
REFORMATORIBVS IO. FRANC. PRIOLO DOCTORE, ZACHARIA
LEONARDO DONATO LQ. INSTAVRATVM ANNO M

Aims

Mortality from breast cancer is declining in most countries thanks to effective screening programs, early diagnosis, molecular characterization of the different subtypes and biology-driven treatments. A multidisciplinary management of breast cancer patients is therefore the key to success and a breast multidisciplinary team should include – besides the “classic” clinical specialties – pathologists, molecular biologists and geneticists. Furthermore, the availability of multiple diagnostic and therapeutic choices, the increasing costs of new technologies and drugs and the issue of sustainability represent a new challenge for socially-responsible clinicians. With this goal in mind, the Programme includes lectures on molecular characterization, updated treatments of early and advanced disease, management of difficult cases and hereditary syndromes and issues of sustainability and drug access across countries.

Clinical case discussions and debates are planned to allow a continuous and fruitful exchange of experiences and opinions between speakers and participants.

In order to reward scientific excellence and to foster international cooperation, the International Scientific Committee of the 16th AIBCC will award the 10th International Prize for Breast Cancer Research to a scientist who has published a breakthrough paper in the previous year. We also welcome the presentation of posters from participants and the best poster will be awarded during the Award Ceremony.

The Digital Event is addressed to medical oncologists, pathologists, breast surgeons, radiation oncologists and basic scientists who will have the opportunity to interact with breast cancer leaders and exchange experiences in a friendly atmosphere.

Addressed to

Gynaecologists and obstetrics, medical oncologists, pathologists, radiologists, radiation oncologists, surgeons. Biologists, pharmacists, and nurses.

» *Async Distance Learning*

September 25th, 2020 – September 24th, 2021

Programme

Invited lectures will be recorded in advance and launched on the virtual platform on September 25th. All the lectures will take 15'

VIRTUAL SESSION I: EVOLUTION IN CANCER PREVENTION AND DIAGNOSIS

- 1. Beyond BRCA1/2: Management of women with other predisposition gene mutations** - Claudine Isaacs
- 2. Tumor infiltrating lymphocytes in breast cancer: role in clinical practice**
Maria Vittoria Dieci
- 3. Clinical impact of genomics for HER2+ and TNBC** - Aleix Prat
- 4. New biomarkers ready for prime time (PDL1, PI3K, BRCA, AR etc)**
Giuseppe Viale

VIRTUAL SESSION II: LOCOREGIONAL TREATMENT, LIFE AFTER BC

- 1. Is it safe to avoid axillary node dissection in SN+ patients?**
Elefterios Mamounas
- 2. PMRT after immediate breast reconstruction: the way forward**
Philip Poortmans
- 3. Hormone replacement therapy after BC treatment** - Fedro Peccatori
- 4. Bone Health** - Ingo Diehl
- 5. Follow up: how, who, why** - Jacek Jassem

VIRTUAL SESSION III: SYSTEMIC TREATMENT FOR EBC

- 1. How to identify HR+ who are likely to benefit from adjuvant chemotherapy** - Carlo Tondini
- 2. Risk adapted endocrine therapy for HR+ BC (from 5 y tamoxifen to 10 years or more AI)** - Sibylle Loibl
- 3. Neoadjuvant therapy for HER2+ disease: new data, new standard?**
Valentina Guarneri
- 4. Is immunotherapy ready for prime time for early TNBC?** - Hope Rugo
- 5. Post-Neoadjuvant treatments: achievements and opportunities**
Pier Franco Conte
- 6. CDK4/6 inhibitors for early breast cancer** - Gabriel N. Hortobagyi

VIRTUAL SESSION IV: ADVANCED BREAST CANCER

- 1. Biomarker driven treatment sequencing for HR+ ABC: attempt to reconcile science and label indications** - Stephen Johnston
- 2. HER2+ disease: integrating the drug tsunami** - Sandra Swain
- 3. TNBC: challenges and opportunities** - Miguel Martin
- 4. New promising drugs for advanced breast cancer** - Giuseppe Curigliano

VIRTUAL SESSION V: AFFORDABILITY OF BREAST CANCER COSTS AND EQUITY IN ACCESS

- 1. The US system: lights and shadows** - Thomas Buchholz
- 2. Reimbursement process in Italy** - Francesco Perrone
- 3. Real World Evidence in Oncology: Opportunities and Pitfalls** - Paolo Bruzzi
- 4. The wave of biosimilars** - Hope Rugo
- 5. The EBCC 2020 Manifesto: how to translate this to clinical reality**
Philip Poortmans

» *Live Webinar*

October 8th-9th, 2020

Programme

Thursday, October 8th

15.50 **Registration of participants**

16.00 **Introduction to the Conference**

Pier Franco Conte, Gabriel N. Hortobagyi, Valentina Guarneri, Philip Poortmans

16.15 **Q&A live session on pre-recorded lectures of session I
Evolution in cancer prevention and diagnosis**

Chairmen: Pier Franco Conte, Valentina Guarneri

The authors of the lectures will be connected. Moderators will pose 2-3 questions selected from those arrived in the days before through the virtual platform.

- **Beyond BRCA1/2: Management of women with other predisposition gene mutations** - Claudine Isaacs
- **Tumor infiltrating lymphocytes in breast cancer: role in clinical practice** - Maria Vittoria Dieci
- **Clinical impact of genomics for HER2+ and TNBC** - Aleix Prat
- **New biomarkers ready for prime time (PDL1, PI3K, BRCA, AR etc)**
Giuseppe Viale

16.45 **Q&A live session on pre-recorded lectures of session II
Locoregional treatment, life after BC**

Chairmen: Pier Franco Conte, Valentina Guarneri, Stefania Migliuolo

The authors of the lectures will be connected. Moderators will pose 2-3 questions selected from those arrived in the days before through the virtual platform.

- **Is it safe to avoid axillary node dissection in SN+ patients?**
Elefterios Mamounas
- **PMRT after immediate breast reconstruction: the way forward**
Philip Poortmans

- **Hormone replacement therapy after BC treatment**

Fedro Peccatori

- **Bone Health** - Ingo Diel

- **Follow up: how, who, why** - Jacek Jassem

17.15

Clinical Case Discussion

- **Clinical case: sentinel node biopsy before/after primary systemic therapy**

Presenter: Tania Saibene

Discussant: Elefterios Mamounas

- **Clinical case: radiation therapy after primary systemic therapy treatment**

Presenter Cristina Falci

Discussant Philip Poortmans

- **Clinical case: pathologic complete response after CT+trastuzumab and pertuzumab?**

Presenter: Federica Miglietta

Discussant. Sandra Swain

- **Clinical case: young patients with TNBC and BRCA+ (discussion on platinum salts, ovarian stimulation for fertility issues, contralateral surgery)**

Presenter: Gaia Griguolo

Discussant: Hesham Ahmed Gaballah Elghazaly

18.15

Virtual Ceremony for the presentation of the University of Padua Award for Advances in Breast Cancer 2020 and best poster award

18.30

Lecture of the Awardee

18.50

Adjourn

Friday October, 9th

16.00 **Introduction**

Pier Franco Conte, Gabriel N. Hortobagyi, Valentina Guarneri, Philip Poortmans

16.15 **Q&A live session on pre-recorded lectures of session III Systemic treatment for EBC**

Chairmen: Pier Franco Conte, Valentina Guarneri

The authors of the lectures will be connected. Moderators will pose 2-3 questions selected from those arrived in the days before through the virtual platform.

- **How to identify HR+ who are likely to benefit from adjuvant chemotherapy** - Carlo Tondini
- **Risk adapted endocrine therapy for HR+ BC (from 5 y tamoxifen to 10 years or more AI)** - Sibylle Loibl
- **Neoadjuvant therapy for HER2+ disease: new data, new standard?** - Valentina Guarneri
- **Is immunotherapy ready for prime time for eTNBC?** - Hope Rugo
- **Post-Neoadjuvant treatments: achievements and opportunities**
Pier Franco Conte
- **CDK4/6 inhibitors for early breast cancer** - Gabriel N. Hortobagyi

16.45 **Q&A live session on pre-recorded lectures of session IV Advanced Breast Cancer**

Chairmen: Pier Franco Conte, Valentina Guarneri

The authors of the lectures will be connected. Moderators will pose 2-3 questions selected from those arrived in the days before through the virtual platform.

- **Biomarker driven treatment sequencing for HR+ ABC: attempt to reconcile science and label indications** - Stephen Johnston
- **HER2+ disease: integrating the drug tsunami** - Sandra Swain
- **TNBC: challenges and opportunities** - Miguel Martin
- **New promising drugs for advanced breast cancer**
Giuseppe Curigliano

17.15

Q&A live virtual session on pre-recorded lectures of session V Affordability of Breast Cancer Costs And Equity In Access

Chairmen: Pier Franco Conte, Valentina Guarneri

The authors of the lectures will be connected. Moderators will pose 2-3 questions selected from those arrived in the days before through the virtual platform.

- **The US system: lights and shadows** - Thomas Buchholz
- **Reimbursement process in Italy** - Francesco Perrone
- **Real World Evidence in Oncology: Opportunities and Pitfalls**
Paolo Bruzzi
- **The wave of biosimilars** - Hope Rugo
- **The EBCC 2020 Manifesto: how to translate this to clinical reality**
Philip Poortmans

17.45

Clinical Case Discussion

- **Clinical case: molecular tumor board and liquid biopsy**
Presenter: Giacomo Pelizzari
Discussant: Hope Rugo
- **Clinical case: oligometastatic disease**
Presenter: Luisa Carbognin
Discussant: Gabriel N. Hortobagyi
- **Clinical case: slowly progressive disease**
Presenter Carlo A. Giorgi
Discussant P. Franco Conte

18.15

Conclusions

Directors

Pier Franco Conte

*Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology
and Gastroenterology
University of Padua (I)*

Valentina Guarneri

*Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and
Gastroenterology
University of Padova (I)*

Gabriel N. Hortobagyi

*Department of Breast Medical Oncology
The University of Texas - MD Anderson Cancer
Center
Houston (USA)*

Philip Poortmans

*Past-president of ECCO
Department of radiation oncology
Iridium Kankernetwerk
University of Antwerp
Wilrijk-Antwerp (B)*

Scientific Committee

Hesham Ahmed Gaballah Elghazaly

*Department of Clinical Oncology and nuclear
medicine
University of Ainshams
Cairo (EG)*

Jacek Jassem

*Department of Oncology and Radiotherapy
Medical University of Gdansk (PL)*

Stephen Johnston

*NIHR Biomedical Research Centre for Cancer
Royal Marsden NHS Foundation
Trust & Institute of Cancer Research
London (UK)*

Sibylle Loibl

*German Breast Group
University of Frankfurt (D)*

Eleuterios Mamounas

*Comprehensive Breast Program
MD Anderson Cancer Center Orlando
Orlando (F)*

Miguel Martin

*Medical Oncology Service
Hospital Universitario Gregorio Marañón
Madrid (E)*

Stefania Migliuolo

*Europa Donna Italia
Milan (I)*

Fedro Alessandro Peccatori

*Department of Medical Oncology
European Institute of Oncology (IEO)
Milan (I)*

Aleix Prat

*Medical Oncology Department
Hospital Clinic
Barcelona (E)*

Sandra Swain M.

*Research Development
Georgetown University Medical Center
Washington (USA)*

Speakers

Paolo Bruzzi
Epidemiologist
Genova (I)

Thomas Buchholz
Radiation Oncology
Scripps Memorial Hospital La Jolla
MD Anderson Cancer Center
Houston (USA)

Luisa Carbognin
Division of Gynecologic Oncology,
Fondazione Policlinico Universitario 'A.
Gemelli' IRCCS,
Roma (I)

Giuseppe Curigliano
Department of Oncology
European Institute of Oncology
University of Milan (I)

Maria Vittoria Dieci
Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and
Gastroenterology
University of Padova (I)

Ingo Diel
Gynaecology Unit
Praxisklinik am Rosengarten
Mannheim (D)

Cristina Falci
Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and
Gastroenterology
University of Padua (I)

Carlo Alberto Giorgi
Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and
Gastroenterology
University of Padua (I)

Gaia Griguolo
Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and
Gastroenterology
University of Padua (I)

Claudine Isaacs
Cancer Center
Georgetown University
Washington (USA)

Federica Miglietta
Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and
Gastroenterology
University of Padua (I)

Giacomo Pelizzari
Department of Oncology
ASU FC
Udine (I)

Francesco Perrone
Clinical Trial Unit, National Cancer Institute
IRCCS Fondazione Pascale
Napoli (I)

Hope Rugo
UCSF Carol Franc Buck Breast Care Center
Breast Oncology Clinical Trials Program
San Francisco (USA)

Tania Saibene
Breast Surgery
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and
Gastroenterology
University of Padua (I)

Carlo Tondini
Division of Oncology
ASST Papa Giovanni XXIII
Bergamo (I)

Giuseppe Viale
Department of Pathology
European Institute of Oncology
University of Milano (I)

Award & Poster Session

UNIVERSITY OF PADUA AWARD FOR ADVANCES IN BREAST CANCER 2020

The Scientific Committee will select young researchers (< 40 years from any country) who have published in an international peer-reviewed journal, as the principal author, a manuscript reporting important clinical or biological advances in breast cancer. The winner will be invited to present his/her study during the annual Conference.

POSTER SESSION

Participants can send one or more abstracts.

The form (available on website <https://meettheprofessor.accmad.org>) should be filled out by following specific guidelines:

1. Use the capital letter for the title
2. Indicate each author's affiliation (that should include institution, department and town)
3. Underline the designated presenting author's name.
4. Use font Times New Roman 10, single line spacing.

Abstracts will be selected by the Scientific Committee and will be shown in the poster session on the website <https://meettheprofessor.accmad.org>.

People sending the selected abstracts will have free registration.

Abstracts should be sent within September, 15th. A confirmation will be sent by email within September 20th.

CME

Based on the in force regulations approved by the CNFC, Accademia Nazionale di Medicina (provider n. 31) will assign to the activity CME:

Async Distance Learning: 9 CME points

Live webinar: 6 CME points

Training objective: professional and technical content (knowledge and skills) specific to each profession, specialisation and highly specialised activity. Rare disease.

The credit certification is subject to:

- Professions/specializations should correspond to those which have been accredited for CME
- attendance at the 100% of the async distance learning and webinar live on the platform fad.accmed.org
- the completion of the Meeting evaluation online form available at the end of the each CME activity
- completion of the final questionnaire (at least 75% of correct answers).

We would like to remind all participants that only 1/3 of CME can come from a sponsorship.

Official Language

The official language of the Meeting is English. No simultaneous translation will be provided.

Registration

The registration fee includes async distance learning and webinar of October, 8th and 9th:

€ 180,00

€ 100,00 for graduate students and nurses

To register, please send:

- registration form duly filled out;
- privacy statement and consent to the use of personal data (as in the back of the form);
- payment

to Accademia Nazionale di Medicina - Galleria Ugo Bassi, 2 40121 Bologna (fax 0039 51 0569162 - e.mail: info.bologna@accmed.org, within **September 15th, 2020**).

Online registration is possible on the website

<http://meettheprofessor.accmed.org>

By submitting the form and the payment, your registration is completed with the exception of specific decisions of the Meeting Secretariat.

Incomplete registration will NOT be admitted.

The registration will be confirmed by e-mail, please put your e-mail address on the registration form.

CANCELLATION

- In order to cancel please give advise with a written communication to Accademia Nazionale di Medicina within 10 days from the beginning. A 70% of the registration fee will be returned. Any cancellation after that deadline will not be reimbursed.

With the patronage of

INSTITUTIONS



PATROCINIO
REGIONE DEL VENETO

1222-2022
800
ANNI



UNIVERSITÀ
DEGLI STUDI
DI PADOVA



SCIENTIFIC SOCIETIES



Endorsed by¹
ESTRO



Organizer

ACCADEMIA NAZIONALE
DI MEDICINA

www.accmed.org



General Manager: Stefania Ledda

www.accmed.org

Via Martin Piaggio, 17/6

16122 Genova

Information:

<http://meettheprofessor.accmed.org>

Ph. 0039 51 0569163 - 51 6360080

info.bologna@accmed.org

Organizing Partner

Forum Service

Via Martin Piaggio, 17/8

16122 Genova